GlassScriptPhysician profile
Crystal S Reese
NPI 1780003822
$4,056.69
in general payments reported to CMS, 2019-2025
34 companies · $696 in 2025
The $696 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $398 · 2021: $294 · 2022: $1,661 · 2023: $346 · 2024: $276 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,069.46 | 2022 | |
| Abbvie INC. | $408.10 | 2019-2023 | |
| Becton, Dickinson and Company | $313.57 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $273.04 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $177.16 | 2019-2025 | Veozah |
| Aspira Women'S Health INC | $154.76 | 2022 | |
| Leo Pharma INC. | $149.27 | 2025 | Anzupgo |
| Dexcom, INC. | $140.54 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Pfizer INC. | $123.07 | 2019-2023 | |
| Pharmacosmos Therapeutics INC. | $121.35 | 2022 | |
| Sage Therapeutics, LLC | $100.52 | 2020-2025 | Zurzuvae |
| Lilly USA, LLC | $96.39 | 2024-2025 | Mounjaro, Zepbound |
| Scynexis, INC. | $95.09 | 2022 | |
| Hologic Sales and Service, LLC | $89.08 | 2022-2025 | Aptima, Myosure Tissue Removal Device |
| Shield Therapeutics INC | $82.97 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $70.65 | 2020 | |
| Ethicon US, LLC | $65.59 | 2020-2022 | |
| Therapeuticsmd, INC. | $62.84 | 2019-2021 | |
| Roche Diagnostics Corporation | $62.45 | 2019-2020 | |
| Organon LLC | $46.92 | 2025 | Nexplanon |
| Mylan Pharmaceuticals INC. | $45.33 | 2020-2022 | |
| Intuitive Surgical, INC. | $42.36 | 2022-2023 | Da Vinci Surgical System |
| Agile Therapeutics, INC. | $41.64 | 2021 | |
| Amag Pharmaceuticals, INC. | $29.64 | 2019 | |
| Exeltis, USA INC. | $29.06 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.05 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $23.10 | 2025 | |
| Mayne Pharma Commercial LLC | $20.16 | 2023 | |
| Myovant Sciences INC. | $19.94 | 2022 | |
| Minerva Surgical, INC | $17.94 | 2023 | |
| Lupin INC. | $17.64 | 2019 | |
| Dysis Medical, INC. | $16.35 | 2020 | |
| Avion Pharmaceuticals | $12.37 | 2022 | |
| Allergan, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Reese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.